Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Cue Biopharma, Inc.NASDAQ: CUE
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$5.36M, compared with -$12.3M a year earlier. Trailing-twelve-month operating income was -$19.58M.
Context
- Operating income amounted to 96.6% of revenue in FY2025, down 350.3 pp from a year earlier.
- Operating income grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 2 analysts of -$82.6M (-211.4%) for the fiscal year ending Dec 2026, a slowdown from the +36.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.36M-373.9% QoQ
- Last fiscal yearDec 2025
- -$26.52M+36.1% YoY
- LTMMar 2026
- -$19.58M+52.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +56.4% | -24.0% | -80.4 pp |
| 1 year | +36.1% | -211.4% | -247.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (26.52M) USD
- Year-over-year change
- +36.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.52M) | +36.1% |
| FY2024 | 2024-12-31 | (41.5M) | +20.4% |
| FY2023 | 2023-12-31 | (52.15M) | +2.0% |
| FY2022 | 2022-12-31 | (53.23M) | -21.8% |
| FY2021 | 2021-12-31 | (43.71M) | — |
Operating Income vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 operating income of -$19.58M is the 3rd highest of the 7 companies compared; the peer median is -$27.19M.
- Its year-over-year change of +52.4% is the highest of 7, against a peer median of -6.6%.
- Operating income amounts to 59.8% of revenue for CUE, versus a peer median of 912.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$12.9M | -15.3% | — | 912.4% | |
| LTM Mar 2026 | -$17.19M | +2.1% | — | 749.7% | |
| LTM Mar 2026 | -$19.58M | +52.4% | — | 59.8% | |
| LTM Mar 2026 | -$20.38M | -42.0% | — | — | |
| LTM Mar 2026 | -$34.01M | +41.4% | — | — | |
| LTM Mar 2026 | -$60.57M | +20.8% | — | 18182.8% | |
| LTM Mar 2026 | -$116.94M | -258.1% | — | — | |
| Peer median (excluding CUE) | -$27.19M | -6.6% | — | 912.4% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.94M | 1.25M | 5.49M | 9.29M | 27.47M |
| Cost of Revenue | (1.78M) | 0 | 38.1M | 0 | 0 |
| Gross Profit | 16.72M | 1.25M | (32.61M) | 9.29M | 27.47M |
| Gross Margin | 111.9% | 100.0% | -593.9% | 100.0% | 100.0% |
| Research & Development | 41.35M | 38.58M | 40.8M | 36.3M | 37.74M |
| Selling, General & Admin | 17.31M | 16.17M | 16.68M | 14.59M | 16.24M |
| Operating Expenses | 60.43M | 54.47M | 19.54M | 50.79M | 53.99M |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 3.48M |
| EBITDA | (45.44M) | (50.49M) | (46.05M) | (37.53M) | (22.27M) |
| EBITDA Margin | -304.1% | -4055.5% | -838.8% | -404.1% | -81.1% |
| Operating Income | (43.71M) | (53.23M) | (52.15M) | (41.5M) | (26.52M) |
| Operating Margin | -292.6% | -4275.1% | -949.9% | -446.9% | -96.6% |
| Interest Income | 45.9K | 928.24K | 2.66M | 1.62M | 807K |
| Interest Expense | 0 | 713.82K | 1.25M | 796K | 357K |
| Other Income / Expenses | 45.9K | 215K | 1.42M | 826K | 419K |
| Income Before Tax | (43.67M) | (53.01M) | (50.73M) | (40.67M) | (26.1M) |
| Pre-Tax Margin | -292.3% | -4257.8% | -924.1% | -438.0% | -95.0% |
| Income Tax Expense | 495K | 0 | 0 | 0 | 500K |
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Net Margin | -295.6% | -4257.8% | -924.1% | -438.0% | -96.9% |
| EPS (Basic) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| EPS (Diluted) | (42.30) | (44.70) | (33.30) | (21.60) | (8.40) |
| Weighted Avg Shares | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
| Weighted Avg Shares (Diluted) | 1.04M | 1.19M | 1.53M | 1.88M | 3.16M |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.